Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1
Recruiting
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Biological: JWCAR201
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 9
- Registration Number
- NCT06517004
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Phase 2
Recruiting
- Conditions
- BRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 130
- Registration Number
- NCT06516289
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
Phase 2
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06513221
Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast Cancer
Recruiting
- Conditions
- Hematological ToxicityTargeted TherapyBreast Cancer
- Interventions
- Other: No intervenrion.
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1000
- Registration Number
- NCT06503380
- Locations
- 🇨🇳
Zhi-Ming Shao, Shanghai, Not US/Canada, China
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis
Phase 2
Recruiting
- Conditions
- NSCLC Stage IV
- Interventions
- Drug: PD-1/PD-L1 inhibitor plus chemotherapyRadiation: SRT/WBRT
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT06501378
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Metastasis
Phase 2
Recruiting
- Conditions
- Brain MetastasesNSCLC Stage IV
- Interventions
- Drug: PD-L1/PD-1 inhibitor and chemotherapyRadiation: SRT or WBRT
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 54
- Registration Number
- NCT06501391
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Effectiveness of Gut Microbiota-targeted Diatery Intervention Among People Living With HIV
Not Applicable
Not yet recruiting
- Conditions
- HIVAtherosclerosisDiet, Healthy
- Interventions
- Dietary Supplement: gut microbiota-targeted dietary intervention
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 110
- Registration Number
- NCT06498401
Predicting Response to Chemotherapy in Colorectal Cancer Via Multi-dimensional Analyses of the Tumor Associated Neutrophils
Completed
- Conditions
- Tumor Associated Neutrophils
- Interventions
- Other: No different intenvention
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 653
- Registration Number
- NCT06495827
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Phase 1
Recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
- Interventions
- Procedure: SurgeryRadiation: Adjuvant radiation
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 27
- Registration Number
- NCT06494943
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
AK104 and Low-dose Radiation in Recurrent/metastatic HNSCC After Failure of First-line Systemic Therapy
Phase 2
Recruiting
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT06494995
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath